deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01566721

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SafeHER)

A Phase III Prospective, Two-Cohort Non-Randomized, Multi-Centre, Multinational, Open-Label Study to Assess the Safety of Assisted- and Self-Administered Subcutaneous Trastuzumab as Therapy in Patients With Operable HER2-Positive Early Breast Cancer

Sponsor: Hoffmann-La Roche

Interventions Herceptin
Updated 24 times since 2017 Last updated: Apr 26, 2021 Started: May 17, 2012 Primary completion: Mar 10, 2015 Completion: Feb 19, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Breast Neoplasms, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 24 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jan 2018 · 7 months · monthly snapshot~Jan 2018 – ~May 2018 · 4 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Apr 2020 · 4 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~May 2021 · 3 months · monthly snapshot~May 2021 – ~Jul 2024 · 38 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

24 versions recorded
  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Nov 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE3

  4. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

Show 19 earlier versions
  1. May 2021 — Jul 2024 [monthly]

    Completed PHASE3

  2. Feb 2021 — May 2021 [monthly]

    Completed PHASE3

  3. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE3

  4. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jun 2020 — Aug 2020 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  6. Apr 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Dec 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Sep 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  9. Jul 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  10. Apr 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

  11. Jan 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  12. Oct 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  13. Jul 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  14. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  15. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  16. Jan 2018 — May 2018 [monthly]

    Active Not Recruiting PHASE3

  17. Jun 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE3

  18. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  19. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .